India has recorded more than 42 Lakh Covid-19 Vaccine jabs in the last 24 hours. With this India’s cumulative Covid-19 vaccination coverage crosses 34 Crore.
According to the CoWin portal, a total of 27.58 crore people have been given the first dose of the vaccine and a total of 5.90 crore people have received their second dose.
The Narendra Modi government is eyeing for gigantic 12 crore Covid jabs in the month of July. Meanwhile, the World Health Organization has said that at least 10 per cent population of each country must be vaccinated against novel coronavirus by September.
Coverage among health and front-line workers, which was lagging for some time has improved recently with 87% of HCWs and 91% FLWs covered with at least first dose, whereas 62% of HCWs and 49% of FLWs are now fully vaccinated. Among people aged 18-44 years, nearly 15% have received at least the first dose. Daman & Diu has achieved the maximum coverage so far under this age band receiving at least the first dose.
Around 45% of over 45 years population has received at least the first dose of the jabs, whereas 11% have got both. Tripura has over 97.9% of its estimated above 45 population vaccinated with at least the first dose.
After June 21, when India made a global record with highest single-day vaccinations as it administered over 86 lakh vaccine jabs in a day, the vaccination rate of the country has dropped by 68 percent with India administering just 27.6 lakh jabs on 30th June.
Eight European Union states, namely- Germany, Slovenia, Austria, Greece, Iceland, Ireland, Spain and Switzerland — have put Covishield vaccine on their list of approved vaccines.
On 1st July, Indian drugmaker Zydus Cadila said, that it has applied to the country’s drug regulator for emergency use approval of its COVID-19 vaccine, ZyCoV-D. If approved, ZyCoV-D will be the first needle-free three dose vaccine.
According to reports, the Covid-19 vaccine developed by Novavax may get approval for use in India between July and September. Novavax Chief Executive Officer has said that It is likely to have a higher price than Serum Institute of India’s Covishield.